Prescriptive Use To Mitigate Radiotherapy Damage To Normal Tissue and Allow More Effective Cancer Therapy
Almost 70% of all patients with cancer receive radiotherapy alone or in combination with surgery or chemotherapy. The amount of radiation that can be used to control tumor growth, however, is limited by normal tissue damage. Development of drugs to selectively reduce radiotherapy-induced normal tissue damage may improve post-therapy quality of life and allow more aggressive radiotherapy protocols to better eliminate tumors and save lives.
TP508 has the potential to mitigate radiation therapy-induced damage to normal cells in a number of different tissues. For example, preclinical studies have shown that TP508 mitigates effects of brain cancer radiation therapy.
- Radiation therapy decreases neurogenesis in hippocampus and can lead to permanent mental Impairment
- 90% of Children under 7 require special education and have learning defects for the rest of their lives
- Adults experience memory loss (10 to 20% drop in IQ) and increased probability of early dementia
- No FDA approved product to solve this problem
TP508 brings the hope of preventing RT brain damage
- Decreases Neuroinflammation
- Regenerates brain cells
- Increases neural function
- Clinical trials expected to show improved memory, cognition, and quality of life
- Mitigates RT damage to normal tissue to allow oncologists to better eradicate tumors
TP508 represents a first-in-class drug to be used in combination with brain cancer radiation therapy to prevent long-term neuronal dysfunction. This drug could significantly change cancer therapy protocols to more effectively eradicate tumor cells, increase cancer patient survival, and increase post-therapy quality of life.